Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIO2STOP combination of pioglitazone and TKIs in CML after failed TKI stop
2024-515460-31-00Phase 2Authorised
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pioglitazone, imatinib, dasatinib, nilotinib and bosutinib in chronic myelogenous leukemia (CML), sponsored by Centre Hospitalier de Versailles. Primary endpoints: Safety - adverse events with pioglitazone plus TKI, Pharmacokinetics of pioglitazone and TKIs and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-515460-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515460-31-00.